| 2
01
This presentation of DarioHealth Corp. (“Dario”, the “Company”, “we” and “our”) and
statements of our management or agents related thereto contain or may contain
forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “Act”). Statements which are not historical reflect our current
expectations and projections about our future results, performance, liquidity, financial
condition, prospects and opportunities and are based upon information currently
available to us and our management and their interpretation of what is believed to be
significant factors affecting our business, including many assumptions regarding
future events. For example, when we discuss our growth potential and return on
investment, the potential synergies as a result of the combination with Twill, our
expected gross margins and reduced operating expenses, the proposed path to
profitability, the potential market opportunity, potential increase in revenue based on
multi-condition accounts, the potential benefits to be realized by the strategic
agreement with Sanofi U.S. Services Inc. (“Sanofi”) and the expected contract value and
potential revenues and product offering, we are using forward-looking
statements. Words such as “seek,” “intend,” “believe,” “plan,” “estimate,” “expect,”
“anticipate,” “will,” “would,” and other similar expressions all denote forward-looking
statements within the meaning of the Act.
Readers are cautioned that actual results, performance, liquidity, financial condition
and results of operations, prospects and opportunities could differ materially and
perhaps substantially from those expressed in, or implied by, these forward-looking
statements as a result of various risks, uncertainties and other factors. Factors that
could cause or contribute to such differences include, but are not limited to our
compliance with regulatory requirements, the impact of current and any future
competition, our current and future capital requirements and our ability to satisfy our
capital needs through financing transactions or otherwise, our ability to manufacture,
market and generate sales of our Dario® diabetes management solution, as well as
other factors and risks discussed in the Company’s filings (including the results of the
Company’s commercial and regulatory plans for Dario®) with the U.S. Securities and
Exchange Commission (the “SEC”).
Forward-looking statement
We undertake no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by
applicable law.
In addition, readers are cautioned that any estimates, forecasts or projections contained
in this presentation or as may be discussed by our management or agents have been
prepared by our management in good faith on a basis believed to be reasonable.
However, such estimates, forecasts and projections involve significant elements of
subjective judgment and analysis and no representation can be made as to their
attainability. No representation or warranty (express or implied) is made or is to be relied
upon as a promise or representation as to our future performance. Readers are
cautioned that such estimates, forecasts or projections have not been audited and have
not been prepared in conformance with generally accepted accounting principles.
This presentation contains market data related to our business and industry, including
projections that are based on a number of assumptions. If these assumptions turn out to
be incorrect, our actual results may differ materially from the projections based on these
assumptions. As a result, the market for our products may not grow at the rates
projected by these data, or at all. If the assumptions upon which the projections are
based prove to be incorrect, or if the market for our products fails to grow at the rates
projected, our results will differ materially from the projections included in this
presentation.
This presentation shall not constitute an offer to sell or the solicitation of an offer to buy
any securities, nor shall there be any sale of any securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
This presentation also contains certain financial information that is presented on a non
GAAP basis. A reconciliation of GAAP to non-GAAP measures has been provided in the
financial statement tables annexed at the end of this presentation. An explanation of
these measures is also included below under the heading "Non-GAAP Financial
Measures." |
